First-in-human testing of a wirelessly controlled drug delivery microchip

Science Translational Medicine

Volumn 4, Issue 122, 2012, Pages

  Farra, Robert ^a   Sheppard, Norman F ^a   McCabe, Laura ^a   Neer, Robert M ^b   Anderson, James M ^c   Santini, John T ^d   Cima, Michael J ^e   Langer, Robert ^e  

^a MicroCHIPS Inc   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d On Demand Therapeutics Inc   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34]; BIOLOGICAL MARKER; CALCIUM;

AGED; AREA UNDER THE CURVE; ARTICLE; BIOCHIP; BIOEQUIVALENCE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE SAFETY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFORMATION PROCESSING; MAXIMUM PLASMA CONCENTRATION; MICROCHIP; OSSIFICATION; OSTEOPOROSIS; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; BONE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; INSTRUMENTATION; METABOLISM; METHODOLOGY; MICROCAPSULE; MICROCHIP ANALYSIS; WIRELESS COMMUNICATION;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; CALCIUM; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICROCHIP ANALYTICAL PROCEDURES; TERIPARATIDE; WIRELESS TECHNOLOGY;

EID: 84863115197     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003276     Document Type: Article

References (27)

1. G. W. Stone, S. G. Ellis, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg, J. J. Popma, M. E. Russell; TAXUS-IV Investigators, A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221-231 (2004).
2. J. T. Santini Jr., M. J. Cima, R. Langer, A controlled-release microchip. Nature 397, 335-338 (1999).
3. A. C. Richards Grayson, I. S. Choi, B. M. Tyler, P. P. Wang, H. Brem, M. J. Cima, R. Langer, Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2, 767-772 (2003).
4. J. H. Prescott, S. Lipka, S. Baldwin, N. F. Sheppard Jr., J. M. Maloney, J. Coppeta, B. Yomtov, M. A. Staples, J. T. Santini Jr., Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat. Biotechnol. 24, 437-438 (2006).
5. J. R. Coppeta, K. Shelton, N. F. Sheppard Jr., D. Snell, C. M. B. Santini, Compression and cold weld sealing methods and devices, U.S. Patent 2006/0115323 A1 (2006).
6. J. M. Maloney, S. A. Uhland, B. F. Polito, N. F. Sheppard Jr., C. M. Pelta, J. T. Santini Jr., Electrothermally activated microchips for implantable drug delivery and biosensing. J. Control. Release 109, 244-255 (2005).
7. J. H. Prescott, T. J. Krieger, S. Lipka, M. A. Staples, Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multireservoir array. Pharm. Res. 24, 1252-1261 (2007).
8. E. R. Proos, J. H. Prescott, M. A. Staples, Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array. Pharm. Res. 25, 1387-1395 (2008).
9. J. M. Anderson, Cardiovascular device retrieval and evaluation. Cardiovasc. Pathol. 2, 199-208 (1993).
10. W. G. Brodbeck, M. MacEwan, E. Colton, H. Meyerson, J. M. Anderson, Lymphocytes and the foreign body response: Lymphocyte enhancement of macrophage adhesion and fusion. J. Biomed. Mater. Res. A 74, 222-229 (2005).
11. L. Perry, F. Karp, K. Hauch, B. D. Ratner, Explanted pacemakers: Observations of the longterm foreign body response. J. Undergrad. Res. Bioeng. 7, 13-21 (2007).
12. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level, Summary Meeting Report, Brussels, Belgium, 5-7 May 2004 (WHO Press, Geneva, Switzerland, 2007).
13. R. Burge, B. Dawson-Hughes, D. H. Solomon, J. B. Wong, A. King, A. Tosteson, Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22, 465-475 (2007).
14. Eli Lilly and Co., Annual Report and Proxy Statement; http://investor.lilly.com/annuals.cfm
15. J. M. Hock, I. Gera, Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res. 7, 65-72 (1992).
16. H. Dobnig, R. T. Turner, The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138, 4607-4612 (1997).
17. C. A. Frolik, E. C. Black, R. L. Cain, J. H. Satterwhite, P. L. Brown-Augsburger, M. Sato, J. M. Hock, Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33, 372-379 (2003).
18. R. M. Neer, C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich, J. Y. Reginster, A. B. Hodsman, E. F. Eriksen, S. Ish-Shalom, H. K. Genant, O. Wang, B. H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001).
19. C. P. Jerome, D. B. Burr, T. Van Bibber, J. M. Hock, R. Brommage, Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28, 150-159 (2001).
20. K. Taylor, D. T. Gold, P. Miller, P. Chen, M. Wong, K. Krohn, Teriparatide therapy in a community setting: Persistence and use of other osteoporosis medications in DANCE, paper presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research, 2008.
21. H. Y. Ahn, Clinical Pharmacology and Biopharmaceutics Review (Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, 2002); http://www.accessdata.fda. gov/drugsatfda-docs/nda/2002/21-318-FORTEO- BioPharmr.pdf
22. A. Kratz, M. Ferraro, P. M. Sluss, K. B. Lewandrowski, Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N. Engl. J. Med. 351, 1548-1563 (2004).
23. J. M. Anderson, Biological responses to materials. Annu. Rev. Mater. Res. 31, 81-110 (2001).
24. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry: Statistical Approaches to Establishing Bioequivalence (Food and Drug Administration, Silver Spring, MD, 2001); http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070244.pdf.
25. European Medicines Agency, Committee for Medicinal Products for Human Use, Guideline on the Investigation of Bioequivalence (European Medicines Agency, London, UK, 2009).
26. S. J. Glover, R. Eastell, E. V. McCloskey, A. Rogers, P. Garnero, J. Lowery, R. Belleli, T. M. Wright, M. R. John, Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45, 1053-1058 (2009).
27. Immutopics Inc., High Sensitivity Human PTH (1-34) ELISA Kit; http://www.immutopics. com/pdf/directional-inserts/60-3900.pdf.